VSTM•Verastem said it will open the TARGET-D 301 first-line mPDAC trial by year-end 2026. It reported confirmed response rates of 50% in second-line pancreatic cancer and 41% in second-line-or-later disease for VERSUS-7375, and expects initial data from a first-line combination study in Q1 2027.
Verastem plans to open the TARGET-D 301 first-line metastatic pancreatic ductal adenocarcinoma trial by year-end 2026 and expects initial data from a first-line VERSUS-7375 combination with GnP in Q1 2027. The company reported a 50% confirmed objective response rate in second-line pancreatic ductal adenocarcinoma and a 41% confirmed response rate with 900 mg once-daily monotherapy in second-line-or-later disease; it also cited two complete responses in second-line-or-later disease, one confirmed.
